From 1 patient, they revealed a MEN1 frameshift-mutation (p.L117fs) and a cooccurring somatic H-RAS (p.Q61R) activating point-mutation present in primary and recurrent tumors.[9] They also found mutations in FAT1 and SND1, which are closely related to MAPK-pathway activation, suggesting that the MAPK signaling pathway may be a novel treatment target of ASCO.[9] Other oncocytoma-related genes reported before are as seen in Fig. 5. The gene discussed is HRAS; the disease is oncocytic adenoma.